RT Journal Article
SR Electronic
T1 PCSK9 inhibition: A promise fulfilled?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S36
OP S44
DO 10.3949/ccjm.83.s2.05
VO 83
IS 11 suppl 2
A1 White, Khendi
A1 Mohan, Chaitra
A1 Rocco, Michael
YR 2016
UL http://www.ccjm.org/content/83/11_suppl_2/S36.abstract
AB The association of reduced proprotein convertase subtilisin/kexin type 9 (PCSK9) activity with reduced cardiovascular disease (CVD) events—and the need for add-ons to statin therapy to achieve treatment goals— has led to the rapid development and US Food and Drug Administration (FDA) approval of monoclonal antibody therapies to inhibit PCSK9. Now that PCSK9 inhibitors are approved by the FDA for use in certain patients, data from ongoing long-term clinical trials addressing tolerability, safety, and proof of additional reduction in CVD events are eagerly awaited